Results 101 to 110 of about 1,044,094 (254)
Addiction, EarlyView.Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr +10 more
wiley +1 more source
RECENT TRENDS IN ACUTE SYNTHETIC CANNABINOID HARMS RESULTING IN AMBULANCE ATTENDANCE
, 2019 RECENT TRENDS IN ACUTE SYNTHETIC CANNABINOID HARMS RESULTING IN AMBULANCE ...
Karen Smith (71943) +9 more
core
SAGE Open Medical Case Reports, 2017 Synthetic cannabinoids refer to a wide variety of chemicals engineered to bind cannabinoid receptors (CB1 and CB2) and mimic the effects of delta-9-tetrahydrocanabinol. The potential for severe toxicity and limited in vivo data make synthetic cannabinoid
Marc-Alain Babi +2 more
doaj +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Exploring the Incidence of Synthetic versus Non-Synthetic Cannabinoid-Induced Psychosis: A Scoping Review [PDF]
Cannabinoids, including synthetic and non-synthetic variants, are associated with diverse mental health outcomes including the development of psychotic symptoms.
Barnard, Marie +3 more
core
Perspectives on drugs: Synthetic cannabinoids in Europe. [PDF]
, 2015 Synthetic cannabinoids represent the largest group of compounds currently monitored in Europe by the EU Early warning system on new psychoactive substances. Current knowledge on these substances, as well as trends in production, availability and use, are
core
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Peripheral targets for neuropathic pain
British Journal of Pharmacology, EarlyView.Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour +3 more
wiley +1 more source
Purification and characterization of heterologously produced cannabinoid receptor 1 and G proteins [PDF]
, 2007 G protein coupled receptors form the largest group of transmembrane proteins, which are involved in signal transduction and are targeted directly or indirectly by 40-50% of the drugs in the market.
Chillakuri, Chandramouli, Chillakuri, C.
core